Table 5 Association between the factors cited by the physician as influencing the choice of therapy and the patient group (total patient population, n = 4 672).
| Factor | All (%) | Adjuvant upfront (%) | Adjuvant, 1–5 years (%) | Adjuvant, 5–10 years (%) | Metastatic disease (%) | p-value |
|---|---|---|---|---|---|---|
| TNM stage | 2 887 (61.8) | 2 616 (62.6) | 115 (57.5) | 21 (53.8) | 135 (53.6) | 0.012 |
| Hormone receptor status | 3 738 (80.0) | 3 386 (81.0) | 140 (70.0) | 29 (74.4) | 183 (72.6) | < 0.001 |
| HER2 status | 917 (19.6) | 865 (20.7) | 20 (10.0) | 3 (7.7) | 29 (11.5) | < 0.001 |
| Type of surgery | 489 (10.5) | 442 (10.6) | 17 (8.5) | 4 (10.3) | 26 (10.3) | 0.830 |
| Previous chemotherapies | 361 (7.7) | 319 (7.6) | 7 (3.5) | 1 (2.6) | 34 (13.5) | < 0.001 |
| Age | 2 269 (48.6) | 2 088 (49.9) | 63 (31.5) | 16 (41.0) | 102 (40.5) | < 0.001 |
| Patientʼs decision | 1 012 (21.7) | 915 (21.9) | 35 (17.5) | 8 (20.5) | 54 (21.4) | 0.531 |
| Tumor Board | 3 551 (76.0) | 3 249 (77.7) | 126 (63.0) | 20 (51.3) | 156 (61.9) | < 0.001 |